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Summary
Objective—Genome-wide association studies have identified many obesity/body mass index 
(BMI)-associated loci in Europeans and East Asians. Since then, a large number of studies have 
investigated the role of BMI-associated loci in the development of type 2 diabetes (T2D). 
However, the results have been inconsistent. The objective of this study was to investigate the 
associations of 11 obesity/BMI with T2D risk and explore how BMI influences this risk.
Methods—We retrieved published literature from PubMed and Embase. The pooled odds ratios 
(OR) with 95% confidence intervals (CI) were calculated using fixed- or random- effect model.
Results—In the meta-analysis of 42 studies for 11 obesity/BMI-associated loci, we observed a 
statistically significant association of FTO rs9939609 polymorphism (66,425 T2D cases/239,689 
normoglycemic subjects; p=1.00×10-41) and six other variants with T2D risk (17,915 T2D cases/
27,531 normoglycemic individuals: n=40,629 to 130,001; all p<0.001 for SH2B1 rs7498665, 
FAIM2 rs7138803, TMEM18 rs7561317, GNPDA2 rs10938397, BDNF rs925946 and NEGR1 
rs2568958). After adjustment for BMI, the association remained statistically significant for four of 
the seven variants (all p<0.05 for FTO rs9939609, SH2B1 rs7498665, FAIM2 rs7138803, 
GNPDA2 rs10938397). Subgroup analysis by ethnicity demonstrated similar results.
Xi et al. Page 2













Conclusions—This meta-analysis indicates that several BMI-associated variants are 
significantly associated with T2D risk. Some variants increase the T2D risk independent of 
obesity, while others mediate this risk through obesity.
Keywords
Type 2 diabetes; Obesity; FTO; Variants; Meta-analysis
Introduction
Obesity is an established risk factor for development of type 2 diabetes (T2D). Many studies 
have investigated the role of obesity/ body mass index (BMI)-associated loci in predicting 
risk of T2D. In 2007, a variant (rs9939609) in the fat mass and obesity-associated (FTO) 
gene was first reported to be statistically significantly associated with obesity [odds ratio 
(OR)=1.32, 95% confidence interval (CI)=1.26-1.39] and with T2D in individuals of 
European descent (OR=1.15, 95%CI=1.09-1.23). 1 However, after adjustment for BMI, a 
surrogate measure of obesity, the significance of association was completely abolished 
(OR=1.03, 95%CI=0.96-1.10), suggesting that the effect of FTO gene polymorphism on 
T2D was mediated through obesity among Europeans. 1 At the same time, Scuteri et al. also 
reported that common variants in the FTO gene were associated with obesity related traits. 2 
Since then, many studies have investigated the FTO-T2D association among different ethnic 
populations and obtained inconsistent results. Following the initial evidence of the BMI-
independent association of FTO variant with T2D in Asians,3 a recent large meta-analysis 
including 96,551 East and South Asians confirmed this observation (crude OR=1.15, 
95%CI=1.09-1.21; after adjustment for BMI: OR=1.10, 95%CI=1.05-1.16).4 However, the 
BMI-independent role of FTO in risk of T2D among Europeans still remains a matter of 
debate;1, 5–20 some studies indicated a significant association with T2D after correction for 
BMI, 5, 15, 17 while others reported a marginal or null association. 1, 5–14, 16, 18–20
Subsequently, many other loci associated with obesity or BMI have been identified 12,21 but 
their association with T2D is also controversial,12,13,18–20,22–24. This may be due to 
insufficient statistical power and/or inter-population heterogeneity. In this study, we 
performed a systematic meta-analysis to investigate 11 of the most commonly studied BMI-
associated variants (FTO rs9939609, SH2B1 rs7498665, FAIM2 rs7138803, TMEM18 
rs7561317, GNPDA2 rs10938397, BDNF rs925946, NEGR1 rs2568958, SEC16B1 
rs10913469, KCTD15 rs29941, ETV5 rs7647305 and MTCH2 rs10838738) for their role in 
predicting risk of T2D.
Materials and methods
Literature and search strategy
To date, more than 50 BMI-associated variants or their proxies have been reportedly 
associated with various metabolic traits, we could use only 11 variants in the present meta-
analysis due to limited data for other variants in the published studies and/or lack of 
response from the authors. 25 We searched the literature databases including PubMed and 
Embase. The search strategy was to identify all possible studies that involved the use of 
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following key words: (FTO or SH2B1 or FAIM2 or TMEM18 or NEGR1 or GNPDA2 or 
SEC16B or KCTD15 or BDNF or ETV5 or MTCH2 or fat mass and obesity associated gene 
or Src-homology-2 (SH2) domain containing putative adaptor protein 1 or fas apoptotic 
inhibitory molecule 2 or transmembrane protein 18 or neuronal growth regulator 1 or 
glucosamine-6-phosphate deaminase 2 or SEC16 homolog B (S. cervisiae) or potassium 
channel tetramerization domain containing 15 or brain derived neurotrophic factor or ets 
variant gene 5 or mitochondrial carrier homolog 2) and (polymorphism or variant or 
variation) and (type 2 diabetes or T2D). The language of publication was restricted to 
English. The reference lists of retrieved articles were curated manually. If more than one 
article was published using the same case series, only the study with the largest sample size 
was included in the meta-analysis. The literature search was last updated on June 20, 2013.
Inclusion criteria and data extraction
We included a study in the meta-analysis if it met all the following inclusion criteria: (1) 
investigated the association of BMI-associated gene variant(s) with T2D; (2) used case-
control or cohort design and (3) provided OR with 95% CI under an additive model or 
sufficient data for calculation of this estimate. Following information was extracted from 
each study: (1) name of the first author, (2) year of publication, (3) country of origin, (4) 
ethnicity of the studied population, (5) study design, (6) number of cases and controls or 
total subjects, (7) sex distribution and the mean ages, (8) mean BMI, and (9) studied single 
nucleotide polymorphisms (SNPs). All articles were independently accessed by two authors 
(BX and DZ) to ensure their compliance with the inclusion/exclusion criteria. Any 
disagreements were resolved through discussion and a consensus decision was reached. All 
included studies had informed consent from all the participants and were approved by the 
appropriate Ethics Committees.
Statistical analysis
We calculated the summary estimate under an additive genetic model in this meta-analysis 
because majority of the included studies only provided OR with 95%CI under this model.4 
We analyzed the associations of 11 BMI-associated gene variants with T2D by calculating 
pooled ORs and 95% CIs. The significance of the OR was determined by a Z test (p<0.05 
was considered statistically significant) and Cochrane’s Q test was performed to test the 
between-study heterogeneity using a cut-off of p<0.10 as statistically significant. We used a 
random- (DerSimonian-Laird method) or fixed- (Mantel-Haenszel method) effects model to 
calculate pooled OR in the presence (p<=0.10) or absence (p>0.10) of heterogeneity, 
respectively. We used Begg’s test and Egger’s test (p<0.05 was considered statistically 
significant) to examine any publication bias. To evaluate the stability of the results, we 
performed sensitivity analysis by removing one study at a time. Statistical analyses for meta-
analyses were performed using STATA version 11.0 (StataCorp LP, College Station, TX, 
USA). The associations were not corrected for multiple testing sine the used loci for 
association testing have strong priors.
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Characteristics of the studies on FTO variant and 10 other BMI associated loci
Details of the process of inclusion/exclusion of various studies in the meta-analysis are 
described in Figure 1. We identified a total of 195 potential relevant articles from the 
literature search. Of these, 146 were excluded at the outset because of obvious irrelevance as 
observed from the title or the abstract (e.g. those articles that evaluated the association of 
FTO gene variant with obesity only, metabolic syndrome, type 1 diabetes, gestational 
diabetes, cardiovascular disease, polycystic ovary syndrome or cancer). In addition, three 
review articles and two meta-analyses were also excluded. Six articles were further excluded 
on account of duplicated publications 22, 26–29 or unavailability of OR with 95% CI values.
25 Therefore, a total of 38 articles met the inclusion criteria 1,3–21, 23,24, 30–45.
Since more than one study on FTO variant was included in each of the articles by Scott et al. 
5 and by Hertel et al., 17 they were considered as separate studies in the meta-analysis. 
Thus, the final meta-analysis included a total of 42 studies (21 studies for Europeans, 15 
studies for East Asians and 6 studies for South Asians) from 35 articles 1, 3–21,23,24,30–45 
that had data on rs9939609 (or proxy [r2>0.85]) variant in FTO gene. Out of 21 studies in 
Europeans, 12 had data on rs9939609, 5 on rs8050136, 2 on rs1121980 and 2 on rs1421085. 
Only one variant was selected if any study analyzed more than one variant, and we used the 
FTO variant rs9939609 to represent other polymorphisms because they are in strong linkage 
disequilibrium (LD) with each other (r2>0.85). All studies provided the crude (except the 
study by Webster et al 16) and BMI-adjusted (except the study by Scott et al 5) ORs with 
95% CIs for FTO-T2D association. Characteristics of the included studies for FTO variant(s) 
in Europeans are listed in Supplementary Table 1.
For 10 other BMI-associated gene variants included in the meta-analysis, the data on 
specific SNPs (or proxies) in specific genes was available in variable number of studies. All 
the variants and their proxies were in strong LD with each other (all r2>0.85 in Hapmap-
CEU, CHB and JPT for each SNP). All studies provided the crude and BMI-adjusted ORs 
with 95%CIs for the association of specific variants with T2D. Characteristics of the 
included studies for these ten loci are listed in Supplementary Table 2. The genotypes of all 
11 BMI-associated variants were in Hardy-Weinberg equilibrium in controls of all included 
studies (all p>0.05).
Meta-analysis results for FTO variant
A total of 66,425 T2D cases and 239,689 normoglycemic controls for FTO rs9939609 (or 
proxy) were identified from all the included studies. We observed a statistically significant 
association of rs9939609 variant with the risk of T2D [(OR=1.14, 95%CI=1.12-1.16, p(z-
test)=1.00×10-41), I2=0.0%, p for heterogeneity=0.386, Table 1]. Interestingly, the 
association remained statistically significant after adjustment for BMI [(OR=1.07, 
95%CI=1.05-1.09, p(z-test)=6.42×10-41, I2=0.0%, p for heterogeneity=0.576)]. In the 
subgroup analysis by ethnicity, similar results were found in Europeans (Table 1 and Figure 
2A and 2B), East Asians and South Asians without or with adjustment for BMI (Table 1).
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Meta-analysis results for 10 other BMI-associated loci
We had a variable number of subjects for association analysis of each BMI-associated gene 
variant with T2D. The sample size in T2D cases ranged from 17,915 to 27,531, and from 
40,629 to 130,001 for normoglycemic controls. We observed a statistically significant 
association of six BMI-associated gene variants with the risk of T2D (SH2B1 rs7498665: 
OR=1.08, 95%CI=1.05-1.12, p(z-test)=2.28×10-7; FAIM2 rs7138803: OR=1.08, 
95%CI=1.05-1.11, p(z-test)=1.35×10-7; TMEM18 rs7561317: OR=1.13, 95%CI=1.06-1.21, 
p(z-test)=4.47×10-4; GNPDA2 rs10938397: OR=1.07, 95%CI=1.03-1.10, p(z-test)= 
5.86×10-5; BDNF rs925946: OR=1.06, 95%CI=1.03-1.10, p(z-test)=1.08×10-4, NEGR1 
rs2568958: OR=1.04, 95%CI=1.01-1.08, p(z-test)=0.015 (Table 1). After adjustment for 
BMI, the associations remained statistically significant for three variants (SH2B1 
rs7498665: OR=1.06, 95%CI=1.02-1.09, p(z-test)=8.71×10-4; FAIM2 rs7138803: OR=1.05, 
95%CI=1.02-1.08, p(z-test)=0.001; GNPDA2 rs10938397: OR=1.04, 95%CI=1.01-1.08, 
p(z-test)=0.021) but was abolished for three other variants (TMEM18 rs7561317, BDNF 
rs925946 and NEGR1 rs2568958) (Table 1). However, we did not observe statistically 
significant associations of four other BMI-associated gene variants (SEC16B rs10913469, 
KCTD15 rs29941, ETV5 rs7647305, MTCH2 rs10838738) with T2D without or with 
adjustment for BMI (Table 1).
In the Europeans, five BMI-associated gene variants (SH2B1 rs7498665, FAIM2 rs7138803, 
TMEM18 rs7561317, GNPDA2 rs10938397 and NEGR1 rs2568958) were significantly 
associated with the risk of T2D. However, the associations remained statistically significant 
for only two variants (SH2B1 rs7498665 and FAIM2 rs7138803) after adjustment for BMI 
(Table 1). In the East Asians, three BMI-associated gene variants (FAIM2 rs7138803, 
GNPDA2 rs10938397 and BDNF rs925946) were significantly associated with the risk of 
T2D without or with adjustment for BMI (Table 1). The overall sample size was adequately 
powered (>90%) to detect the association.
Sensitivity analysis and publication bias
We performed sensitivity analysis by excluding one study at a time. The results confirmed 
the statistically significant association between 11 BMI-associated variants and the risk of 
T2D without or with adjustment for BMI (data not shown). There was no evidence of any 
publication bias for all the variants (p>0.05 for Begg’s test and Egger’s test).
Discussion
In this study, we performed an extensive review and meta-analysis to investigate the role of 
BMI-associated gene variants in predicting risk of T2D. Our study indicates that in addition 
to FTO, polymorphisms in six other BMI associated genes (SH2B1, FAIM2, TMEM18 
GNPDA2, BDNF and NEGR1) were statistically significantly associated with an increased 
risk of T2D in Europeans and East Asians. Associations of variants in four genes including 
FTO, SH2B1, FAIM2 and GNPDA2 with T2D may not be entirely mediated via obesity 
(BMI).
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The FTO gene on chromosome 16q12.2 was first identified as a susceptibility locus for T2D 
in Europeans by genome-wide association study (GWAS). 1 However, based on complete 
abolition of the FTO variant-T2D association on adjustment for BMI, the study concluded 
that the effect of the FTO variant on T2D was fully mediated through adiposity. 1 
Subsequently, many individual studies have reported inconsistent results. 1, 5–20 A recent 
meta-analysis of the association between FTO variant and incident T2D in three cohorts 
showed influence of the FTO variant on the risk of T2D independent of BMI. 17 In the 
present study, we also found that BMI had no substantial impact on the association between 
FTO rs9939609 variant and risk of T2D and the association was observed irrespective of 
ethnicity. Our meta-analysis includes probably the largest sample size to date investigating 
this association and hence the results are highly convincing. In addition, we observed a 
similar effect size among Europeans and Asians with or without adjustment for BMI, 
suggesting a global role for FTO variants in predicting an independent risk for T2D.
Two recent GWAS studies initially designed to identify obesity susceptibility loci reported 
10 other BMI-associated gene variants. 12, 21 Although several studies have investigated the 
associations of these reported variants with T2D, results have not been replicated. Since 
obesity is one of the main risk factors for T2D, exploration of obesity-associated genes in 
the development of T2D has important implications. We have recently established the 
association of BMI-associated variant in MC4R with risk of T2D and demonstrated no 
influence of BMI on the strength of association. 46 Our present observations provide 
evidence of possible existence of two types of obesity-associated genetic variants that could 
explain the link between obesity and T2D; most increase risk of T2D through obesity, while 
some have independent association with T2D. To our knowledge, no meta-analysis on this 
aspect has been performed and our results might shed light on the underlying mechanism on 
how obesity increases the risk of T2D.
It is still not clear how variants in the BMI associated genes could independently influence 
the risk of T2D. As is known, the FTO protein is highly expressed in the central nervous 
system (CNS) and regulates energy metabolism. 21 Many studies have also indicated that 
variants in FTO influences energy-dense food intake rather than regulation of energy 
expenditure. 47 In addition, FTO variants are reported to be associated with diabetes-related 
metabolic traits (including higher fasting insulin, glucose and triglycerides, and lower HDL 
cholesterol), although the associations disappeared after adjustment for BMI.48 
Furthermore, the FTO is also highly expressed in muscle, and a recent study supported an 
important role of FTO in oxidative metabolism, lipogenesis and oxidative stress in muscle, 
49 which suggests its potential involvement in the muscle defects that characterize T2D. 
Similar to FTO, SH2B1, FAIM2, TMEM18, NEGR1, GNPDA2 and BDNF are also highly 
expressed in the CNS and thus may play influence the above mentioned traits.21 SH2B1 is 
specifically implicated in the insulin signaling pathway and Sh2b1-null mice tend to have 
high-fat diet-induced hyperglycemia, hyperinsulinemia, and glucose intolerance.50 NEGR1 
plays an important role in neuronal outgrowth.51 BDNF is suggested to regulate blood 
glucose homeostasis and insulin sensitivity peripherally.52 The potential role of FAIM2, 
TMEM18, and GNPDA2 proteins in T2D associated pathophysiological processes needs to 
be investigated further.
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Our data shows that although the association of several of BMI-associated variants with type 
2 diabetes is statistically significant, their effect size is small. 53 This suggests that globally 
BMI-associated SNPs may play relatively small role in the pathophysiology of T2D. 
However, majority of the T2D-associated variants identified to date influence beta-cell 
function rather than insulin resistance and hence it may not be unreasonable to assume that 
BMI-associated variants might have more of an effect on insulin resistance than on beta-cell 
dysfunction.54 This may also explain why majority of these variants do not predict strong 
risk for T2D.
Our meta-analysis is subject to several limitations. First, BMI is not the ideal measure of 
obesity and adjustment for BMI may not fully consider the effect of obesity on variant-T2D 
association. Other measures of obesity such as waist circumference and waist-hip ratio 
should be taken into account in future studies. Second, the diabetic status and subsequent 
anti-diabetic treatment or life-style intervention may influence adiposity and BMI. Third, we 
cannot rule out the well-known reporting biases that have been identified after the onset of 
diseases like T2D, and thus prospective studies will be superior to cross-sectional designs 
for answering such questions with reasonable confidence. Fourth, since most of the studies 
included in this meta-analysis did not provide data on diet, physical activity and other 
metabolic variables, we could not address their influence on the effect of FTO variant on 
obesity and obesity comorbidity. Fifth, to date only three studies 13, 18, 20 have examined 
the cumulative risk of several obesity-associated loci (some in the form of genetic risk score) 
on T2D, which impeded our attempts of pooled analysis. Finally, in this meta-analysis, we 
only included published studies, thus, the exclusion of unpublished data may bias the results. 
To overcome these limitations, a nested T2D case-control (matched for ethnicity, sex, age, 
adiposity) recruited from a multi-ethnic prospective study seems to be an optimal design to 
properly assess the association of obesity-related variants with T2D risk.
In conclusion, our meta-analysis with sufficient statistical power has confirmed the 
statistically significant associations of seven BMI-associated genes (FTO, SH2B1, FAIM2, 
TMEM18, BDNF, GNPDA2, NEGR1) with risk of T2D in Europeans or East Asians, and 
several variants seem to predict risk of T2D, independent of BMI. However, observations on 
several other BMI-associated genes in the development of T2D could not be replicated. The 
findings suggest that it will be important to dissect the pathways that separate the roles of 
these variants in the risk of T2D.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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without and (B) with adjustment for body mass index
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